Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-6552 + diltiazem
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**MK-6552 + diltiazem** is a combination of two small molecule drugs, administered together in clinical pharmacology studies to assess possible pharmacokinetic interactions and safety profiles. MK-6552 is under investigation as a treatment for narcolepsy type 1, with a mechanism that is not publicly disclosed, but it is being developed by Merck Sharp & Dohme. Diltiazem is a long-approved calcium channel blocker, often used to treat hypertension, angina, and certain arrhythmias, functioning as a non-dihydropyridine L-type calcium channel (CACNA1C) inhibitor. The combination is currently being studied in healthy adult participants to evaluate effects on drug levels and potential drug-drug interactions[1][3][8].
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on MK-6552 + diltiazem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-6552 + diltiazem.